Sebastian Stintzing

List of Publications by Year in Descending Order

221 papers	5,709 citations	35 h-index	71 g-index
305 ext. papers	7,019 ext. citations	4.7 avg, IF	5.67 L-index

#	Paper	IF	Citations
221	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. *Journal of Clinical Oncology*, **2022**, 40, 143-143	2.2	
220	Incidence, severity, and onset of oral mucositis in 5-FU based chemotherapy for gastrointestinal cancer.. *Journal of Clinical Oncology*, **2022**, 40, 77-77	2.2	
219	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized PhaseIII trial FIRE-3 (AIO KRK-0306). *International Journal of Cancer*, **2022**, 150, 112-123	7.5	2
218	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.. *Frontiers in Oncology*, **2022**, 12, 751453	5.3	0
217	Efficacy, Molecular Biology, Quality of Life, or Economic Aspects: What Do We Really FOCUS oN?. *Journal of Clinical Oncology*, **2022**, JCO2102310	2.2	2
216	FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.. *BMC Cancer*, **2022**, 22, 359	4.8	
215	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer.. *Critical Reviews in Oncology/Hematology*, **2022**, 173, 103646	7	0
214	Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.. *OncoImmunology*, **2022**, 11, 2068109	7.2	0
213	Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. *Frontiers in Oncology*, **2021**, 11, 772809	5.3	0
212	FIRE-7-Studie (AIO-KRK-0120) **2021**, 36, 244-246	0.2	
211	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. *Molecular Cancer Therapeutics*, **2021**, 20, 1153-1160	6.1	0
210	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. *Cancers*, **2021**, 13,	6.6	1
209	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). *European Journal of Cancer*, **2021**, 147, 128-139	7.5	0
208	AIO-FIRE-8-Studie (AIO-KRK/YMO-0519) **2021**, 36, 251-252	0.2	
207	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. *Journal of Clinical Oncology*, **2021**, 39, 3502-3502	2.2	7
206	Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).. *Journal of Clinical Oncology*, **2021**, 39, 3503-3503	2.2	2
205	The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. *Journal of Clinical Oncology*, **2021**, 39, 3581-3581	2.2	

204	RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).. *Journal of Clinical Oncology*, **2021**, 39, 3566-3566	2.2	0
203	Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).. *Journal of Clinical Oncology*, **2021**, 39, 3571-3571	2.2	
202	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. *Scientific Reports*, **2021**, 11, 12191	4.9	0
201	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. *Cancer Treatment Reviews*, **2021**, 97, 102172	14.4	9
200	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 150, 133-142	7.5	1
199	Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. *Journal of Gastrointestinal Surgery*, **2021**, 25, 58-66	3.3	2
198	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. *British Journal of Cancer*, **2021**, 124, 587-594	8.7	18
197	Systemische Therapie des metastasierten Kolonkarzinoms. *Onkologe*, **2021**, 27, 259-266	0.1	
196	Importance and Qualitative Requirements of Magnetic Resonance Imaging for Therapy Planning in Rectal Cancer - Interdisciplinary Recommendations of AIO, ARO, ACO and the German Radiological Society. *RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren*, **2021**, 193, 513-520	2.3	1
195	Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. *Journal of Clinical Oncology*, **2021**, 39, 118-118	2.2	
194	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. *Frontiers in Oncology*, **2021**, 11, 670396	5.3	4
193	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). *International Journal of Cancer*, **2021**, 149, 1935-1943	7.5	1
192	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. *Genome Medicine*, **2021**, 13, 116	14.4	3
191	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. *Cancer Treatment Reviews*, **2021**, 98, 102218	14.4	7
190	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. *European Journal of Cancer*, **2021**, 153, 86-95	7.5	2
189	Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. *Oncologist*, **2021**, 26, e2110-e2114	5.7	3
188	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). *Journal of Clinical Oncology*, **2021**, JCO2101332	2.2	8
187	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). *European Journal of Cancer*, **2021**, 157, 71-80	7.5	0

186	Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. *Cancers*, **2020**, 12,	6.6	12
185	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2077-2087	4.9	6
184	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. *Clinical Colorectal Cancer*, **2020**, 19, 291-300.e5	3.8	1
183	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. *Annals of Surgical Oncology*, **2020**, 27, 2389-2401	3.1	7
182	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. *European Journal of Cancer*, **2020**, 131, 89-97	7.5	3
181	Therapiesequenz beim metastasierten kolorektalen Karzinom. *InFo Hämatologie + Onkologie*, **2020**, 23, 15-21	0	
180	Perioperative Therapie des CRC. *InFo Hämatologie + Onkologie*, **2020**, 23, 10-14	0	
179	AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS268-TPS268	2.2	1
178	Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. *Cureus*, **2020**, 12, e7305	1.2	2
177	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. *Journal of Clinical Oncology*, **2020**, 38, 245-245	2.2	0
176	Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. *Journal of Clinical Oncology*, **2020**, 38, 187-187	2.2	
175	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).. *Journal of Clinical Oncology*, **2020**, 38, e16055-e16055	2.2	
174	High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.. *Journal of Clinical Oncology*, **2020**, 38, 4026-4026	2.2	
173	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2101-2104	4.9	3
172	Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). *Annals of Oncology*, **2020**, 31, 72-78	10.3	9
171	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. *Journal of Medical Economics*, **2020**, 23, 448-455	2.4	3
170	Palliative Chemo- und Immuntherapie – State of the Art und neue Entwicklungen. *Gastroenterologe*, **2020**, 15, 300-309	0.1	
169	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. *ESMO Open*, **2020**, 5, e001001	6	3

168	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). *European Journal of Cancer*, **2020**, 137, 81-92	7.5	1
167	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. *European Journal of Cancer*, **2020**, 137, 250-259	7.5	5
166	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. *ESMO Open*, **2020**, 5,	6	31
165	Amphiregulin Expression Is a Predictive Biomarker for Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. *Clinical Cancer Research*, **2020**, 26, 6559-6567	12.9	6
164	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. *Anti-Cancer Drugs*, **2020**, 31, 856-865	2.4	0
163	Partition: a surjective mapping approach for dimensionality reduction. *Bioinformatics*, **2020**, 36, 676-681	7.2	2
162	FIRE-5-Studie (AIO TF-0118) **2019**, 34, 367-368	0.2	
161	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
160	Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. *Lancet Oncology, The*, **2019**, 20, e274-e283	21.7	30
159	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. *European Journal of Cancer*, **2019**, 111, 138-147	7.5	3
158	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. *International Journal of Cancer*, **2019**, 145, 2082-2090	7.5	0
157	Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). *Journal of Clinical Oncology*, **2019**, 37, 22-32	2.2	24
156	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 146-157	9.7	67
155	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2019**, 25, 134-141	12.9	28
154	FIRE-6 Studie **2019**, 34, 371-373	0.2	1
153	Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial. *Lancet Oncology, The*, **2019**, 20, 1036-1037	21.7	5
152	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. *Frontiers in Oncology*, **2019**, 9, 849	5.3	67
151	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. *World Journal of Gastroenterology*, **2019**, 25, 3136-3150	5.6	37

150	Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases. *Cancer Research and Treatment*, **2019**, 51, 187-193	5.2	2
149	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2	
148	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. *Journal of Clinical Oncology*, **2019**, 37, 3048-3048	2.2	0
147	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. *Annals of Oncology*, **2019**, 30, 1796-1803	10.3	77
146	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. *Clinical Colorectal Cancer*, **2019**, 18, e8-e19	3.8	9
145	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. *European Journal of Cancer*, **2019**, 107, 100-114	7.5	5
144	Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *European Journal of Cancer*, **2019**, 106, 115-125	7.5	9
143	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. *International Journal of Cancer*, **2019**, 144, 569-581	7.5	11
142	Molekulare Stratifizierung von kolorektalen Karzinomen □was hat Relevanz f□ die klinische Praxis?. *Tumor Diagnostik Und Therapie*, **2018**, 39, 29-32	0.1	1
141	Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. *European Journal of Radiology*, **2018**, 100, 124-129	4.7	2
140	The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 473, 199-207	5.1	10
139	A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. *Pharmacogenomics Journal*, **2018**, 18, 43-48	3.5	1
138	Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. *Pharmacogenomics Journal*, **2018**, 18, 262-269	3.5	2
137	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. *International Journal of Cancer*, **2018**, 142, 1047-1055	7.5	8
136	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2018**, 18, 623-632	3.5	4
135	Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. *European Radiology*, **2018**, 28, 4839-4848	8	5
134	CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. *European Radiology*, **2018**, 28, 5284-5292	8	11
133	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. *PLoS ONE*, **2018**, 13, e0193640	3.7	3

132	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. *Clinical Colorectal Cancer*, **2018**, 17, 215-222.e3	3.8	3
131	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.. *Journal of Clinical Oncology*, **2018**, 36, 800-800	2.2	1
130	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clinical Cancer Research*, **2018**, 24, 784-793	12.9	14
129	Recent advances in understanding colorectal cancer. *F1000Research*, **2018**, 7,	3.6	10
128	Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). *Annals of Oncology*, **2018**, 29, viii39	10.3	2
127	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. *Frontiers in Oncology*, **2018**, 8, 474	5.3	11
126	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. *Oncotarget*, **2018**, 9, 30279-30288	3.3	3
125	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. *ESMO Open*, **2018**, 3, e000353	6	30
124	Genetic variants associated with colorectal brain metastases susceptibility and survival. *Pharmacogenomics Journal*, **2017**, 17, 29-35	3.5	6
123	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. *Pharmacogenomics Journal*, **2017**, 17, 528-534	3.5	7
122	Antibodies for Treatment of Metastatic Colorectal Cancer **2017**, 217-244		
121	Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. *European Journal of Cancer*, **2017**, 79, 50-60	7.5	75
120	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *European Journal of Cancer*, **2017**, 70, 87-98	7.5	311
119	Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. *Anti-Cancer Drugs*, **2017**, 28, 717-722	2.4	11
118	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. *International Journal of Cancer*, **2017**, 141, 1222-1230	7.5	14
117	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. *International Journal of Cancer*, **2017**, 141, 383-392	7.5	5
116	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. *European Journal of Cancer*, **2017**, 77, 13-20	7.5	15
115	Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). *International Journal of Cancer*, **2017**, 140, 1918-1925	7.5	11

114	Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). *European Journal of Cancer*, **2017**, 84, 262-269	7.5	3
113	Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care. *Langenbecks Archives of Surgery*, **2017**, 402, 1223-1232	3.4	6
112	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. *European Journal of Cancer*, **2017**, 84, 69-80	7.5	136
111	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. *Annals of Oncology*, **2017**, 28, 2780-2785	10.3	19
110	FIRE-4.5-Studie **2017**, 32, 54-56	0.2	3
109	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. *Pharmacogenomics Journal*, **2017**, 17, 543-550	3.5	9
108	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA Oncology*, **2017**, 3, 194-201	13.4	409
107	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. *Journal of Clinical Oncology*, **2017** , 35, 3510-3510	2.2	30
106	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). *Oncotarget*, **2017**, 8, 105749-105760	3.3	25
105	Multidisciplinary treatment of colorectal liver metastases. *Minerva Medica*, **2017**, 108, 527-546	2.2	8
104	Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. *Pharmacogenomics Journal*, **2016**, 16, 312-9	3.5	11
103	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. *Visceral Medicine*, **2016**, 32, 178-83	2.4	25
102	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 1426-1434	21.7	246
101	Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) a retrospective, central evaluation of FIRE-3. *Annals of Oncology*, **2016**, 27, vi154	10.3	4
100	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. *Molecular Cancer Therapeutics*, **2016**, 15, 1740-5	6.1	7
99	Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. *Cancer Treatment Reviews*, **2016**, 45, 97-104	14.4	4
98	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. *Clinical Cancer Research*, **2016**, 22, 3218-26	12.9	16
97	CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC?. *Cureus*, **2016**, 8, e591	1.2	1

96	Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. *Annals of Oncology*, **2016**, 27, 1746-53	10.3	127
95	Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). *International Journal of Cancer*, **2016**, 138, 739-46	7.5	25
94	A still missing piece of the FIRE-3 puzzle - Authors' reply. *Lancet Oncology, The*, **2016**, 17, e516	21.7	1
93	CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *Annals of Oncology*, **2016**, 27, 1565-72	10.3	20
92	A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2016**, 67, 11-20	7.5	40
91	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. *Annals of Oncology*, **2015**, 26, 332-9	10.3	20
90	Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). *European Journal of Cancer*, **2015**, 51, 1927-36	7.5	113
89	Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials. *Acta Oncologica*, **2015**, 54, 187-93	3.2	14
88	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. *Acta Oncologica*, **2015**, 54, 993-1000	3.2	5
87	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. *Annals of Oncology*, **2015**, 26, 1728-33	10.3	6
86	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. *Anti-Cancer Drugs*, **2015**, 26, 371-8	2.4	8
85	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. *Pharmacogenetics and Genomics*, **2015**, 25, 30-7	1.9	11
84	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. *Annals of Oncology*, **2015**, 26, 2450-6	10.3	20
83	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2374-81	6.1	3
82	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 3718-26	2.2	89
81	KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. *Future Oncology*, **2015**, 11, 1919-29	3.6	7
80	Diffusion-weighted MRI Before and After Robotic Radiosurgery (Cyberknife®) in Primary and Secondary Liver Malignancies: A Pilot Study. *Technology in Cancer Research and Treatment*, **2015**, 14, 191-9	2.7	6
79	Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. *Hematology/Oncology Clinics of North America*, **2015**, 29, 43-60	3.1	24

78	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2015**, 15, 69-76	3.5	24
77	Forscher und Arzt ein Widerspruch? **2015**, 30, 335-337	0.2	
76	Wahl der Behandlungsstrategie auf der Basis molekularer Marker. *Im Focus Onkologie*, **2015**, 18, 51-59	0	
75	Under-expression of β3 integrin aggravates experimental atherosclerosis. *Journal of Pathology*, **2015**, 236, 5-16	9.4	6
74	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. *International Journal of Cancer*, **2015**, 137, 678-85	7.5	63
73	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. *Pharmacogenomics Journal*, **2015**, 15, 521-9	3.5	8
72	TAS-102, a novel antitumor agent: a review of the mechanism of action. *Cancer Treatment Reviews*, **2015**, 41, 777-83	14.4	80
71	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. *Cancer*, **2015**, 121, 1898-905	6.4	9
70	Sym004: Truly a New Level of Anti-EGFR Treatment?. *Cancer Discovery*, **2015**, 5, 578-80	24.4	1
69	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. *Journal of Clinical Oncology*, **2015**, 33, 3552-3552	2.2	1
68	Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. *Journal of Clinical Oncology*, **2015**, 33, 621-621	2.2	
67	Treatment until progression: Data of the on-treatment population of the FIRE-3 (AIO KRK-0306) study.. *Journal of Clinical Oncology*, **2015**, 33, 3589-3589	2.2	
66	Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. *Clinical Cancer Research*, **2014**, 20, 3064-70	12.9	11
65	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1065-75	21.7	1169
64	Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. *Journal of Cancer Research and Clinical Oncology*, **2014**, 140, 1607-14	4.9	90
63	Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor. *Annals of Surgical Oncology*, **2014**, 21, 2563-72	3.1	24
62	CT fluoroscopy-guided percutaneous fiducial marker placement for CyberKnife stereotactic radiosurgery: technical results and complications in 222 consecutive procedures. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 760-8	2.4	39
61	Management of colorectal cancer. *F1000prime Reports*, **2014**, 6, 108		57

60	Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population. *Annals of Oncology*, **2014**, 25, v1	10.3	34
59	2Nd-Line Therapies After 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (Fire 3)- Trial. *Annals of Oncology*, **2014**, 25, iv172	10.3	2
58	Panitumumab : leading to better overall survival in metastatic colorectal cancer?. *Expert Opinion on Biological Therapy*, **2014**, 14, 535-48	5.4	1
57	Panitumumab safety for treating colorectal cancer. *Expert Opinion on Drug Safety*, **2014**, 13, 843-51	4.1	9
56	Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306). *Annals of Oncology*, **2014**, 25, ii117	10.3	17
55	2ND-Line Therapies After 1st-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (MCRC)-Analysis of the AIO KRK 0306 (FIRE 3)- Trial. *Annals of Oncology*, **2014**, 25, ii112	10.3	2
54	FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply. *Lancet Oncology, The*, **2014**, 15, e583-e584	21.7	12
53	Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. *Molecular Cancer Therapeutics*, **2014**, 13, 528-39	6.1	27
52	Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. *Pharmacogenetics and Genomics*, **2014**, 24, 539-47	1.9	2
51	Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. *Pharmacogenetics and Genomics*, **2014**, 24, 588-96	1.9	8
50	Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). *Anti-Cancer Drugs*, **2014**, 25, 212-8	2.4	38
49	Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. *Journal of Clinical Oncology*, **2014**, 32, 3521-3521	2.2	1
48	Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.. *Journal of Clinical Oncology*, **2014**, 32, 3600-3600	2.2	24
47	Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. *Journal of Clinical Oncology*, **2014**, 32, 445-445	2.2	48
46	AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.. *Journal of Clinical Oncology*, **2014**, 32, 3592-3592	2.2	
45	Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. *Journal of Clinical*	2.2	
44	High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797).. *Journal of Clinical Oncology*, **2014**, 32, 3632-3632	2.2	
43	Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. *Journal of Clinical Oncology*, **2014**, 32, 3571-3571	2.2	

42	Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. *International Journal of Cancer*, **2013**, 132, 236-45	7.5	59
41	Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone. *Langenbecks Archives of Surgery*, **2013**, 398, 265-76	3.4	13
40	KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, **2013**, 139, 953-61	4.9	13
39	Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. *Annals of Oncology*, **2013**, 24, 3051-5	10.3	8
38	Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. *British Journal of Cancer*, **2013**, 109, 1428-36	8.7	17
37	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2203-20	4	4
36	Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. *Cancer Science*, **2013**, 104, 718-24	6.9	45
35	Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. *Acta Oncologica*, **2013**, 52, 971-7	3.2	37
34	Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group". *International Journal of Cancer*, **2013**, 132, 1719-20	7.5	
33	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. *Acta Oncologica*, **2013**, 52, 956-62	3.2	47
32	Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. *Anti-Cancer Drugs*, **2013**, 24, 969-74	2.4	10
31	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. *Molecular Cancer Therapeutics*, **2013**, 12, 2261-72	6.1	17
30	Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. *Clinical Cancer Research*, **2013**, 19, 225-35	12.9	51
29	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. *Journal of Clinical Oncology*, **2013**, 31, LBA3506-LBA3506	2.2	43
28	Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value.. *Journal of Clinical Oncology*, **2013**, 31, 521-521	2.2	
27	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. *Journal of Clinical Oncology*, **2013**, 31, LBA3506-LBA3506	2.2	1
26	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. *Annals of Oncology*, **2012**, 23, 1693-9	10.3	70
25	Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. *Oncology*, **2012**, 83, 241-7	3.6	20

24	Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status. *Colorectal Cancer*, **2012**, 1, 423-432	0.8	
23	The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. *International Journal of Cancer*, **2012**, 131, 980-6	7.5	37
22	Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. *British Journal of Cancer*, **2012**, 107, 1678-83	8.7	31
21	Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. *Anti-Cancer Drugs*, **2012**, 23, 666-73	2.4	12
20	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.. *Journal of Clinical Oncology*, **2012**, 30, 3588-3588	2.2	
19	Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer.. *Journal of Clinical Oncology*, **2012**, 30, 3541-3541	2.2	1
18	Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. *Journal of Clinical Oncology*, **2011**, 29, 1050-8	2.2	92
17	Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. *Clinical Colorectal Cancer*, **2011**, 10, 317-24	3.8	4
16	Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. *Anti-Cancer Drugs*, **2011**, 22, 913-8	2.4	38
15	A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. *BMC Cancer*, **2011**, 11, 367	4.8	8
14	Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. *British Journal of Cancer*, **2011**, 105, 206-11	8.7	19
13	Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 214143		16
12	Role of cannabinoid receptors and RAGE in inflammatory bowel disease. *Histology and Histopathology*, **2011**, 26, 735-45	1.4	15
11	Primary testicular lymphoma: a strictly homogeneous hematological disease?. *Oncology Reports*, **2010**, 23, 1261-7	3.5	15
10	Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. *European Journal of Cancer*, **2010**, 46, 1026-32	7.5	22
9	Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. *Annals of Surgical Oncology*, **2010**, 17, 2877-83	3.1	24
8	Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 455, 171-85	5.1	24
7	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treatment Reviews*, **2009**, 35, 262-71	14.4	157

6	The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. *Pancreatology*, **2009**, 9, 116-26	3.8	35
5	The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. *Deutsches Ärzteblatt International*, **2009**, 106, 202-6	2.5	15
4	Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. *Pancreatology*, **2005**, 5, 387-97	3.8	18
3	Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. *Annals of Vascular Surgery*, **2005**, 19, 310-9	1.7	33
2	Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. *Atherosclerosis*, **2003**, 168, 153-62	3.1	34
1	The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: In reply. *Deutsches Ärzteblatt International*,	2.5	78